This clinical trial, randomized, double-blind study, was done on 80 non-addicted patient with intoxication with methadone. Inclusion criteria: age 20 to 60 years, obtaining informed consent from a parent or guardian patients into the study.
Exclusion criteria: drug, pregnancy and breastfeeding, history of uncontrolled systemic underlying disease, especially liver disease (liver failure, hepatitis, etc.), cardiovascular disease and heart rhythm, especially supraventricular dysrhythmias ; at the same time multiple trauma, especially trauma to the head and the possibility of increased ICP; a history of seizures; a history of hypersensitivity to naloxone or naltrexone consumption in the past; recent use of narcotic analgesics, complications during the administration of a drug abuser.Patients administered an initial dose of 4.0 to 2 mg amount of naloxone (1 to 5 injections of 4.0 mg naloxone) and diluted intravenous or without dilution (in case of loss of consciousness, a history of addiction) and are when the patients returned to consciousness, the initial dose is repeated every 2 to 3 minutes. After awareness of patients and monitor acute toxicity, patients random 1: 1 into two groups of 40 (group 1: receiving naloxone for conservative treatment, group 2 received naltrexone for the treatment of preservatives) are included.
Group 1, 3/2 dose that the patient's consciousness was caused in the first hour, 3/2 × 3/2 initial dose in the second hour, 3/2 × 3/2 × 3/2 initial dose in the third hour and 3 / 2 × 3/2 × 3/2 × 3/2 initial dose of the fourth hour, every hour infusions received.
Group 2, equivalent dose of naloxone that consciousness is, in the form of Naltrexone receiving oral form. Vital signs and other clinical parameters in hours, 1, 2, 3, 4 and 12 after recovery consciousness, were recorded. Data were analyzed using SPSS 18 statistical software.